Gilead Says New Hepatitis Drug Does Not Infringe Merck IP

Law360, New York (September 3, 2013, 3:26 PM EDT) -- Gilead Sciences Inc. has asked a federal court in California to issue a declaratory judgment that its hepatitis C drug would not infringe two Merck & Co. Inc. patents, or to deem the patents invalid, according to a suit filed Friday.

Foster City, Calif.-based Gilead said it has received calls and an email from Merck offering to license the rights to the two patents covering Merck's Victrelis hepatitis C drug for an allegedly untenable amount, in an attempt to prevent Gilead’s competing medication from hitting the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.